发明申请
WO2013148333A1 SALICYLIC ACID DERIVATIVES USEFUL AS GLUCOCEREBROSIDASE ACTIVATORS
审中-公开
作为葡萄糖激酶活化剂有用的盐酸衍生物
- 专利标题： SALICYLIC ACID DERIVATIVES USEFUL AS GLUCOCEREBROSIDASE ACTIVATORS
- 专利标题（中）： 作为葡萄糖激酶活化剂有用的盐酸衍生物
-
申请号： PCT/US2013/032253申请日： 2013-03-15
-
公开(公告)号： WO2013148333A1公开(公告)日： 2013-10-03
- 发明人: MARUGAN, Juan, Jose , ZHENG, Wei , PATNAIK, Samarjit , SOUTHALL, Noel , SIDRANSKY, Ellen , GOLDIN, Ehud , WESTBROEK, Wendy , AFLAKI, Elma , ROGERS, Steven, Andrew , SCHOENEN, Frank, John
- 申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , THE UNIVERSITY OF KANSAS , MARUGAN, Juan, Jose , ZHENG, Wei , PATNAIK, Samarjit , SOUTHALL, Noel , SIDRANSKY, Ellen , GOLDIN, Ehud , WESTBROEK, Wendy , AFLAKI, Elma , ROGERS, Steven, Andrew , SCHOENEN, Frank, John
- 申请人地址： National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard Suite 325, MSC 7660 US
- 专利权人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES,THE UNIVERSITY OF KANSAS,MARUGAN, Juan, Jose,ZHENG, Wei,PATNAIK, Samarjit,SOUTHALL, Noel,SIDRANSKY, Ellen,GOLDIN, Ehud,WESTBROEK, Wendy,AFLAKI, Elma,ROGERS, Steven, Andrew,SCHOENEN, Frank, John
- 当前专利权人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES,THE UNIVERSITY OF KANSAS,MARUGAN, Juan, Jose,ZHENG, Wei,PATNAIK, Samarjit,SOUTHALL, Noel,SIDRANSKY, Ellen,GOLDIN, Ehud,WESTBROEK, Wendy,AFLAKI, Elma,ROGERS, Steven, Andrew,SCHOENEN, Frank, John
- 当前专利权人地址： National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard Suite 325, MSC 7660 US
- 代理机构： MAXWELL, Leslie-Anne
- 优先权： US61/616,758 20120328
- 主分类号： C07C235/64
- IPC分类号： C07C235/64 ; A61K31/167 ; A61P3/00 ; C07C237/22
摘要：
Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R 1 -R 13 , m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.
